Vitekta, Genvoya (elvitegravir) is a small molecule pharmaceutical. Elvitegravir was first approved as Vitekta on 2014-09-24. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Stribild's patents are valid until 2026-10-26 (FDA).
|Drug Class||Antivirals: integrase inhibitors|